Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...

Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation ...

Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates ...

These submissions would initiate the next stage of clinical development for SIL204 in patients with advanced localized KRAS-driven pancreatic cancer.